Bone Mineral Density Response to Long-Term Bisphosphonate Treatment and Discontinuation in a Real-World Clinical Service
Authors:
- 4 May 2023
- journal article
- research article
- Published by Elsevier in Endocrine Practice
- Vol. 29 (8) , 601-605
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronateJournal of Bone and Mineral Research, 2013
- Effect of Stopping Risedronate after Long-Term Treatment on Bone TurnoverThe Journal of Clinical Endocrinology & Metabolism, 2011
- Increases in Hip and Spine Bone Mineral Density are Predictive for Vertebral Antifracture Efficacy with IbandronateCalcified Tissue International, 2010
- Relationship Between Changes in BMD and Nonvertebral Fracture Incidence Associated With Risedronate: Reduction in Risk of Nonvertebral Fracture Is Not Related to Change in BMDJournal of Bone and Mineral Research, 2005
- Assessment of Urinary Bone Markers for Monitoring Treatment of OsteoporosisClinical Chemistry, 2004
- Seven Years of Treatment with Risedronate in Women with Postmenopausal OsteoporosisCalcified Tissue International, 2004
- Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapyBone, 2004
- Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal WomenNew England Journal of Medicine, 2004
- Response of Bone Mineral Density to Once-Weekly Administration of RisedronateEndocrine Practice, 2002
- Antifracture Efficacy of Antiresorptive Agents Are Related to Changes in Bone DensityThe Journal of Clinical Endocrinology & Metabolism, 2000